A study published in November in the American Journal of Clinical Pathology that Emerson co-authored validated the analyzer against the Sysmex XN Automated Hematology System and found that CytoChip's ...

The test will be reimbursed at the price of $1,495 for Medicare patients during the initial nine-month ADLT period starting on April 1.

Such tests are increasingly moving beyond their origins in cutting-edge research and into the laboratory and diagnostic ...

The collaboration will involve the development of algorithms to aid the assessment of complex and difficult-to-scan samples, including bone marrow biopsies.

The deal is part of BioReference's ongoing effort to streamline its business to achieve profitability and follows the sale last year of clinical laboratory assets to Labcorp.

The test will be reimbursed at the price of $1,495 for Medicare patients during the initial nine-month ADLT period starting on April 1.

NEW YORK – Former Magellan Diagnostics CEO Amy Winslow pleaded guilty to violating the federal Food, Drug and Cosmetic Act in a case related to the malfunctioning of Magellan's lead-testing devices.

Last week, readers were most interested in a story about a lawsuit brought forth by Qiagen against BioMérieux in Germany.

Founded in 2009, CLIA-certified Pathline, which also holds College of American Pathologists and New York State Department of Health certifications, provides a range of lab services, including ...

While electronic exchange of orders and results is commonplace in the commercial lab world, public health labs struggle with inconsistent levels of connectivity.

One ACED project is focused on developing biomarkers for the early detection of ovarian cancer, with the goal of commercializing any resulting tests.

The test measures a protein biomarker and can be used to diagnose and manage patients with the progressive autoimmune disorder.